Considering the outstanding anti-tumor effect of silencing RanBP3 in both imatinib sensitive and resistant CML cells (Figures 2, 3), it is necessary to investigate the relationship between RanBP3 and imatinib sensitivity in these cells. The gene discussed is RANBP3; the disease is neoplasm.